Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Isala
University of California, San Diego
Wake Forest University Health Sciences
QuantumLeap Healthcare Collaborative
University of Ulm
Dana-Farber Cancer Institute
Children's Hospital Medical Center, Cincinnati
Essen Biotech
University of California, San Diego
University of California, San Diego
M.D. Anderson Cancer Center
Centre Leon Berard
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
University of Kentucky
University of California, San Diego
The University of Texas Health Science Center, Houston
NuCana plc
Duke University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Aetion, Inc.
Aetion, Inc.
University Health Network, Toronto
The Netherlands Cancer Institute
Sunnybrook Health Sciences Centre
H. Lee Moffitt Cancer Center and Research Institute
Aetion, Inc.
Melanoma Institute Australia
Canadian Myeloma Research Group
Lithuanian University of Health Sciences
Fudan University
M.D. Anderson Cancer Center
Peter MacCallum Cancer Centre, Australia
National University Hospital, Singapore
Royal Free Hospital NHS Foundation Trust
RenJi Hospital
Vall d'Hebron Institute of Oncology
Abramson Cancer Center at Penn Medicine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NYU Langone Health
Pancreatic Cancer Research Team
Case Comprehensive Cancer Center